# Neuralink — Healthcare Investment Intelligence

> medical_device · Series E. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) and describes its goal as creating a general-purpose, high-bandwidth interface to the brain. It has advanced into human clinical trials, including a first human implant in January 2024 and Health Canada approval for a first clinical trial in Canada in November 2024.

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series E
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-29. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.